The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

Pharma brands spend billions annually trying to engage healthcare providers (HCPs), yet much of this outreach has a limited ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

As the prospect of sector-specific tariffs under the second Trump administration continues to rattle drugmakers, a more ...

An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump ...

As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Employees of companies regulated by the FDA—such as pharmas or biotechs—are no longer allowed to serve as members of FDA ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companie | ...